High-Throughput Biomarker Discovery for Clinical Trial Optimization
This webinar shares how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data are being leveraged for robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.
In this webinar, Dr Mo Jain will share how Sapient has established discovery-as-a-service approaches that utilize next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data assets across more than 100,000 individuals to enable robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.
You will learn about:- The role of small molecule biomarkers in providing insight into human disease biology and drug response
- Technologies enabling rapid identification of small molecule biomarkers of biological processes, disease progression, and drug response, including for clinical trial optimization
- Real-world examples of how Sapient’s small molecule biomarker discovery approaches have been used to advance clinical trials
Speaker Biographies
Dr Mo Jain
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. Prior to founding Sapient, he formed, and was director of, Jain Laboratory at the University of California San Diego. There he led a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across population-scale human studies, supported by over $30M in federal, foundation, and industry funding.Â